吉里德科技(Gilead Sciences)公司开发的吸入式抗生素Cayston(氨曲南吸入剂)于2010年3月获得美国FDA批准上市,用于改善因绿脓杆菌感染所致囊肿性纤维化(cystic fibrosis,CF)患者的呼吸状况。绿脓杆菌引起的慢性呼吸道感染可导致肺功能衰退,这与CF发病率及死亡率密切相关。氨曲 The inhaled antibiotic Cayston (aztreonam inhaler) developed by Gilead Sciences was approved by the US FDA in March 2010 for the purpose of improving cystic fibrosis due to Pseudomonas aeruginosa infection, CF) patient’s respiratory status. Chronic respiratory infections caused by Pseudomonas aeruginosa can lead to lung function decline, which is closely related to the incidence of CF and mortality. Ammonia song